GPR32
MOLECULAR TARGETG protein-coupled receptor 32
GPR32 (G protein-coupled receptor 32) is targeted by 27 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting GPR32
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Dehydroepiandrosterone | 0.69 | 1 |
| 2 | Fluoxetine | 0.69 | 1 |
| 3 | amlexanox | 0.69 | 1 |
| 4 | Aripiprazole | 0.69 | 1 |
| 5 | Astemizole Antihistamine drug now withdrawn from | 0.69 | 1 |
| 6 | Chlorhexidine | 0.69 | 1 |
| 7 | Ciclopirox | 0.69 | 1 |
| 8 | clofilium tosylate | 0.69 | 1 |
| 9 | Dehydroepiandrosterone | 0.69 | 1 |
| 10 | Deslanoside Deacetyllanatoside C. | 0.69 | 1 |
| 11 | Disulfiram | 0.69 | 1 |
| 12 | Doxazosin | 0.69 | 1 |
| 13 | lonidamine | 0.69 | 1 |
| 14 | Lynestrenol | 0.69 | 1 |
| 15 | Vitamin K 3 | 0.69 | 1 |
| 16 | Mestranol | 0.69 | 1 |
| 17 | Metergoline | 0.69 | 1 |
| 18 | Methimazole | 0.69 | 1 |
| 19 | Niflumic Acid | 0.69 | 1 |
| 20 | Norethindrone | 0.69 | 1 |
| 21 | Ouabain | 0.69 | 1 |
| 22 | Oxymetholone | 0.69 | 1 |
| 23 | Oxyphenbutazone | 0.69 | 1 |
| 24 | Polidocanol | 0.69 | 1 |
| 25 | Promethazine | 0.69 | 1 |
| 26 | Quinestrol | 0.69 | 1 |
| 27 | Salmeterol Xinafoate | 0.69 | 1 |
About GPR32 as a Drug Target
GPR32 (G protein-coupled receptor 32) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 27 compounds with documented GPR32 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
GPR32 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.